Introducing The Next Generation of Virus Production: TransIT-VirusGEN® Transfection Reagent
Madison, Wis. (November 8, 2017) ‒ Life science researchers now have a single transfection formulation to allow them to produce consistent and high functional titers of adeno-associated virus (AAV) and lentivirus. The new TransIT-VirusGEN® Transfection Reagent is ideal for adeno-associated virus (AAV) and lentivirus production in adherent and suspension cell cultures, and is scalable. TransIT-VirusGEN® Transfection Reagent also supports our virus application portfolio that includes TransIT®-Lenti Transfection Reagent, an optimized solution specific for lentivivrus production, developed by Mirus Bio scientists a year ago.
“The premise of TransIT-VirusGEN® is to give researchers the ability to achieve more with less effort and still obtain high quality, reliable results,” said Scott Hayes, Ph.D., Vice President of Commercial Operations. “We introduced TransIT®-Lenti just over a year ago to address the needs of researchers working with lentivirus” Hayes said. “By adding the ability to now work with adeno-associated virus with TransIT-VirusGEN®, we provide relevant viral production solutions giving researchers confidence in their experiments, removing any uncertainty with their results.”
TransIT-VirusGEN® is unique as it addresses AAV production in adherent and suspension formats but can also be used for adherent and suspension lentivirus production. “With the foresight of those researchers that utilize both recombinant lentivirus and AAV platforms or perhaps move from adherent to suspension formats, we developed one transfection formulation, TransIT-VirusGEN®, to address a gap in workflow,” said Laura Juckem, Ph.D., Vice President of Scientific Operations. “This flexibility and the elimination of unnecessary steps allows for high virus titer production and enables success in downstream transduction experiments.”
With the introduction of this new virus production transfection reagent, interested researchers can visit www.mirusbio.com/virusgen for comprehensive information about the TransIT-VirusGEN® Transfection Reagent and request a free sample.
CONTACT:
Laura Juckem, Ph.D.
Vice President, Scientific Operations
Mirus Bio LLC
Ph: 608.441.2852
Fax: 608.441.2849
Email: laura.juckem@mirusbio.com
Scott Hayes, Ph.D.
Vice President, Commercial Operations
Mirus Bio LLC
Ph: 608.441.2852
Fax: 608.441.2849
Email: scott.hayes@mirusbio.com